Astria Therapeutics (ATXS) Income towards Parent Company: 2017-2018
Historic Income towards Parent Company for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$5.9 million.
- Astria Therapeutics' Income towards Parent Company fell 6.65% to -$5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.0 million, marking a year-over-year increase of 5.05%. This contributed to the annual value of -$26.0 million for FY2018, which is 4.93% up from last year.
- According to the latest figures from Q4 2018, Astria Therapeutics' Income towards Parent Company is -$5.9 million, which was down 1.27% from -$5.8 million recorded in Q3 2018.
- Astria Therapeutics' Income towards Parent Company's 5-year high stood at -$5.5 million during Q4 2017, with a 5-year trough of -$7.9 million in Q1 2017.
- Over the past 2 years, Astria Therapeutics' median Income towards Parent Company value was -$6.8 million (recorded in 2017), while the average stood at -$6.7 million.
- Data for Astria Therapeutics' Income towards Parent Company shows a peak YoY increase of 16.70% (in 2018) and a maximum YoY decrease of 6.65% (in 2018) over the last 5 years.
- Astria Therapeutics' Income towards Parent Company (Quarterly) stood at -$5.5 million in 2017, then dropped by 6.65% to -$5.9 million in 2018.
- Its Income towards Parent Company was -$5.9 million in Q4 2018, compared to -$5.8 million in Q3 2018 and -$6.6 million in Q2 2018.